Sanofi licenses 5 drugs to Covis

04/8/2013 | Pharmaceutical Business Review Online · Drug Store News

Switzerland's Covis Pharma agreed to acquire the U.S. commercial rights to five drugs from Sanofi-Aventis and its units. The deal covers the prostate cancer drug Nilandron; Plaquenil, a drug for malaria, lupus and arthritis; amyotrophic lateral sclerosis drug Rilutek; Uroxatral, a drug for enlarged prostate; and high-potassium treatment Kayexalate. Sanofi keeps the products' rights elsewhere in the world.

View Full Article in:

Pharmaceutical Business Review Online · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA